Cardiac rehabilitation (CR) is a well-endorsed but underused modality for treating patients with known coronary artery disease. The objectives of this study were to examine the use of CR by assessing CR attendance after referral and to assess the relationship between completion of CR and outcomes of mortality and resource use in a large cohort of CR patients referred for CR. A prospective analysis of a well-described cohort of subjects referred for CR was undertaken. Of 5886 subjects referred to CR, only 2900 (49.3%) completed the program, with men more likely to complete CR than women (52.1% vs 38.4%; PϽ0.001). Median follow-up was 5.37 years (interquartile range, 3.24 to 8.87 years). CR completion was associated with reduced mortality (hazard ratio, 0.57; 95% confidence interval, 0.46 -0.66), reduced hospitalization (hazard ratio, 0.75; 95% confidence interval, 0.69 -0.81), and reduced cardiac hospitalization (hazard ratio, 0.61; 95% confidence interval, 0.51-0.74). Using propensity scores, we matched 2256 CR completers to noncompleters. In the propensity-matched cohort, CR remained associated with improved mortality (hazard ratio, 0.67; 95% confidence interval, 0.54 -0.81). These findings confirm reduced mortality in association with CR as seen in other studies, but in a larger, better-described population, while also newly demonstrating a significant reduction in hospitalization. Given the increasing number of subjects surviving initial cardiac events, the importance of completing a CR program to reduce future risk of hospitalization and mortality needs to be recognized. See p 677.
Racial and Ethnic Differences in Incident Hospitalized Heart Failure in Postmenopausal Women: The Women's Health Initiative
Heart failure is increasing in prevalence, especially in older women, with differences noted by race/ethnicity. However, limited information is available on differences by race/ethnicity on the incidence of heart failure, which may differ from previous studies owing to the small number of cases of incident heart failure in racial/ethnic minorities and the incomplete assessment of potential biases. In addition, the potential mechanisms for these differences, including the role of traditional risk factors, lifestyle, socioeconomic status, and access-to-care issues in women, are not well explored. This study confirmed previous findings that black women had the highest rates of heart failure, especially at younger ages, but also demonstrated that this increased risk was completely abated when household income or diabetes mellitus was taken into account. Hispanic and Asian/Pacific Islander women not from the Indian subcontinent had lower rates of heart failure compared with whites, and this protective effect persisted after adjustment for all the above risk factors. Future research on the genetic and environmental interactions that lead to the differential rate of heart failure by race/ethnicity and the risk factors involved may lead to improved targeted preventive therapies. See p 688.
High Levels of Circulating Epinephrine Trigger Apical Cardiodepression in a ␤ 2 -Adrenergic Receptor/ G i -Dependent Manner: A New Model of Takotsubo Cardiomyopathy
Takotsubo cardiomyopathy is an increasingly recognized clinical syndrome characterized by severe acute (but reversible) apical ventricular dysfunction, ST elevation, and unobstructed coronary arteries. Physical or emotional stress is a frequent precipitant, as well as iatrogenic catecholamine exposure. We generated a model of Takotsubo cardiomyopathy using a single high bolus dose of epinephrine in anesthetized rats, which reproduced the reversible apical hypocontractility. We explored the subcellular mechanisms and identified that high-dose epinephrine activated a switch of ␤ 2 -adrenergic receptor (␤ 2 AR) coupling from the positively inotropic G s -cAMP to a negatively inotropic G i signaling pathway. Norepinephrine, which does not activate this G s /G i switch, did not precipitate apical dysfunction. Proportionately higher ␤ 2 AR numbers at the apex produced the apical-basal gradient in contractility. Prevention of the switch increased sudden death in this model, which is consistent with the protective antiarrhythmic and antiapoptotic nature of G i signaling. We screened various ␤-blockers (given after apical dysfunction was established) using the model and noted that propranolol, which also switches ␤ 2 AR to the G i pathway, exacerbated contractile dysfunction without increasing mortality. Carvedilol had similar but less pronounced effects, and bisoprolol did not affect the response. Avoiding the ␤AR-cAMP axis with the calcium myofilament sensitizer levosimendan, we were able to completely rescue the acute Takotsubo syndrome, with 100% survival. This model suggests that an epinephrine-induced ␤ 2 AR G s /G i switch is responsible for the acute apical dysfunction in Takotsubo cardiomyopathy but that it may also confer an element of protection against damage by high catecholamines. See p 697.
Noninvasive Magnetic Resonance Imaging Evaluation of Endothelial Permeability in Murine Atherosclerosis Using an Albumin-Binding Contrast Agent
Despite the systemic and multifactorial nature of atherosclerosis, lesion development is focal and occurs at particular regions of the vasculature including the branches, the inner curvature, and the outer wall of bifurcations, where focal hemodynamic factors exert major damage on the vascular endothelium. Although several imaging modalities are now available for imaging of atherosclerosis, most of the work has focused on identifying anatomic changes associated with disease progression and risk, which have shown low predictive value. Conversely, the combination of imaging structural and functional properties of the vessel wall may allow investigation of the manner in which the extent of local artery disease is related to the degree of local abnormal endothelial function. Therefore, noninvasive physiological imaging of endothelial permeability and function may offer a comprehensive methodology for monitoring focal atherosclerotic progression in both early and later stages, as well as plaque instability, and testing the effectiveness of treatment interventions targeting vascular endothelium integrity and function. See p 707.
Left Bundle-Branch Block Induced by Transcatheter Aortic Valve Implantation Increases Risk of Death
Transcatheter aortic valve implantation (TAVI) has proved to be a valuable treatment in patients with severe, symptomatic aortic valve stenosis who do not qualify for surgery. The TAVI procedure is frequently complicated by new-onset left bundle-branch block (LBBB). Although this complication has been addressed in TAVI literature, no attention has been paid to its clinical relevance, despite ample evidence of unfavorable outcome in other patient populations.
Our multicenter study, comprising 679 TAVI patients from 8 centers in the Netherlands, convincingly shows that TAVI-induced LBBB is one of the strongest predictors of all-cause mortality. The observed Ϸ60% increase in mortality caused by TAVI-induced LBBB suggests that the benefit of valve repair is largely neutralized when LBBB develops. Mortality risk of LBBB was independent of the device type used; however, the incidence of LBBB was Ͼ4 times higher with the use of the Medtronic CoreValve System device than with the Edwards SAPIEN device (51% versus 12%) . This is the first study indicating the considerable importance of LBBB in the outcome of TAVI patients. More attention should be paid to avoiding LBBB in TAVI procedures, both by implanters and by vendors of TAVI devices. With an approximately 50% rate of LBBB and an approximately 20% rate of permanent pacemaker implantations, the studied Medtronic CoreValve System prostheses (until 2010) performed significantly worse than the Edwards SAPIEN devices with regard to both patient outcome and healthcare costs. LBBB should be regarded as a serious adverse event when evaluating new TAVI devices. See p 720.
Cyclin-Dependent Kinase 5-Mediated Hyperphosphorylation of Sirtuin-1 Contributes to the Development of Endothelial Senescence and Atherosclerosis
Aging is a major risk factor for cardiovascular diseases. Endothelial senescence represents one of the early aging characteristics during the development of atherosclerosis in human arteries. SIRT1 is an enzyme responsible for deacetylating a diverse range of protein targets. The role of its yeast homolog, Sir2p, in lifespan extension was reported in the late 1990s. Since then, a vast amount of information has supported the potential antiaging activity of SIRT1 in rodents and humans. This study identified an important posttranslational modification (S47 phosphorylation) of SIRT1 that was augmented during endothelial senescence. By inhibition of the upstream kinase (cyclin-dependent kinase 5), the development of atherosclerosis and vascular inflammation in mice was significantly halted. This evidence demonstrates that SIRT1 is an antivascular aging factor and that it may be a promising therapeutic target for cardiovascular diseases. See p 729.
Elevated Vascular Endothelial Growth Factor Receptor-2 Abundance Contributes to Increased Angiogenesis in Vascular Endothelial Growth Factor Receptor-1-Deficient Mice
Vascular endothelial growth factor receptor-1 (VEGFR-1) is a pleiotropic factor with important roles in biological processes such as vasculogenesis, angiogenesis, arteriogenesis, vascular maturation, and vascular permeability. Clinically, VEGFR-1 has been implicated in a variety of diseases. Elevated levels of VEGFR-1 are a hallmark of preeclampsia, and VEGFR-1 is also thought to mediate atherosclerotic plaque thrombosis through macrophage recruitment. Additionally, VEGFR-1 may play a role in promoting proliferation of tumor vasculature and may aid in exacerbating pathological angiogenesis in other ischemic conditions from retinopathy of prematurity in the retina to myocardial infarction in the heart. VEGFR-1 is expressed mainly on the surface of endothelial cells as well as monocytes and macrophages. Current literature supports conflicting roles for VEGFR-1, depicting it as both a positive and a negative modulator of angiogenesis, thus creating confusion when one attempts to define its role in development and disease. Thus far, the exact role of VEGFR-1 is confusing because of its heterogeneous interactions with other molecules such as its specific ligands VEGF-B and placental growth factor as well as with VEGF-A and VEGFR-2. This is further complicated by the scarcity of in vivo studies performed at the level of the receptor itself. Given the direct involvement of VEGFR-1 in disease and the ambiguous nature of its action in different biological contexts, this study aims to shed light on this enigmatic molecule. Using a VEGFR-1 conditional knockout system, we have found that VEGFR-1 may be an attractive target for proangiogenic therapies. See p 741.
